*To the Editor*:

I applaud Dr. Dempsey and colleagues on their recent article, "Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis," investigating the effects of nintedanib and pirfenidone in idiopathic pulmonary fibrosis (IPF) ([@bib1]). This study provides the first description of these medications in real-world clinical practice and compares patients with IPF who received antifibrotic therapy with matched subjects who received no antifibrotic therapy. The article's illustration of patients and their demographics was heartening, especially given pulmonologists' experience in caring for patients significantly older than those included in the INPULSIS (Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis) and ASCEND (Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis) trials ([@bib2], [@bib3]). Their findings support the use of antifibrotic therapies perhaps in a larger cohort than is typically perceived to derive benefit from them.

Despite the retrospective nature of this study, the authors were able to apply an extremely rigorous methodology to ascertain the effects of these medications by using propensity score matching and local International Classification of Diseases (ICD)-9 and ICD-10 validation strategies. One additional step that might shed further light on antifibrotic effects would be to control the analysis for treatment origin site (i.e., whether the prescribing physician originated from an academic center or a community practice). As interstitial lung disease physicians, we perceive high levels of discordance among interstitial lung disease diagnoses between academic and community physicians ([@bib4]). Numerous drivers explain these discrepancies, including variability in regular multidisciplinary conference participation and the infrequency with which providers may see these complex patients ([@bib5], [@bib6]). Regular practices such as multidisciplinary conferences are associated with higher diagnostic accuracy rates ([@bib7]).

One could speculate about what the actual rate of "true" IPF diagnoses is in the insurance database used in this article, given the retrospective nature of the study and the use of ICD codes to identify patients. The authors astutely recognize these limitations in their discussion, although there appear to be opportunities to further enrich this analysis. Accounting for the origination site of antifibrotic therapy would provide a greater degree of confidence that they are identifying patients with IPF, as those patients would run the gauntlet of the multidisciplinary conference and would be more likely to be cared for by practitioners experienced with IPF. One representative example of this point is the large number of patients with rheumatoid arthritis, which would suggest an alternative diagnosis in \>8% of the dataset's population. Although it is not a certainty, one could envision that such misinterpretations would not occur in a setting that has more experience with this kind of patient. It is unclear what effect this modification would have on the study results, but the degree of benefits may even be intensified given that academic center--affiliated clinicians would likely have more experience in prescribing these medications, as well as more expertise in managing their adverse effects.

I would again like to commend the authors for this tremendous article demonstrating the practical effects of antifibrotics over a half decade after their approval by the U.S. Food and Drug Administration. I hope the article spurs further research in the field of IPF and leads clinicians to offer more patients the option of antifibrotic therapy.
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